Dear CreakyJoints Australia Community:
There is an urgent opportunity for our voices to be heard by the Australian Government’s Department of Health, during an upcoming Pharmaceutical Benefits Advisory Committee (PBAC) meeting. We’re notifying you about how you can participate, and we’re urging you to consider taking a few minutes to help.
The PBAC meets periodically to review a wide range of new treatments and determine their approval process and coverage for patients in need of these medicines.
As we’ve noted in the past, the PBAC has an EXCELLENT process for soliciting feedback from the public, and it’s important that our community share our perspective and lend our voice to their process. Based on the questions asked, they are genuinely interested in hearing from us, which is great. Now it’s (y)our turn to do the talking.
According to the agenda for the upcoming July PBAC meeting, baricitinib, which studies have shown to be a fast-acting and effective new treatment (in the form of a pill) to treat severe active rheumatoid arthritis, is under consideration. Because so many of us share a diagnosis of rheumatoid arthritis, this is great news to be able to ‘add another tool to our tool box’ – a philosophy about medicines CreakyJoints Australia believes strongly in – especially when it comes to new approaches to taking medicine (like a pill versus an injection or an infusion).
Please take a moment to submit a personal comment to the PBAC. It’s easy, it won’t take more than a few minutes of your time, and it is a critical part of our national health process. Don’t have rheumatoid arthritis? That’s OK. You may still comment as an interested and passionate member of the CreakyJoints Australia community.
Note the upcoming deadline is 7 June – right around the corner! – and to help you along with the process, we have cut and pasted the questions you’ll be asked below the link you need to click to begin the submission. Once you have made your submission, please email us at firstname.lastname@example.org so we can tally the numbers. Feel free to share with us the feedback you shared with PBAC, as we are always interested in hearing from our community.
You may also email with any questions or comments that you’d like to ask or share with us privately.
Reminder, the deadline is 7 June.
Step 1: Click on this link to go to the PBAC submission page.
Step 2: Fill out the form on that link, which will correspond to the below questions.
Step 3: Email us notifying us that you have submitted a comment.
Step 4: Send this email to any friends or family who may be interested in helping to raise our voice as arthritis patients!
Medicine to which this submission relates: Baricitinib
Date of PBAC meeting: July 2017
Submitted by: Your name
Email: Your email
Phone number: Your phone
Street address: Your address
Suburb: Your suburb
State: Your state
Post code: Your post code
Declaration of interest: Please include any declarations you wish to make regarding the PBAC submission upon which you are commenting. If you have no declarations to make, please respond “nil”:
Please indicate whether you are a person with this medical condition, a friend or family member, a prescriber, a representative of an organisation or other interested person.
What comments would you like the PBAC to take into account when it considers this submission?
This is where you post your personal experience. Note that this is not a “test” and all submissions will be reviewed by the committee and are appreciated for their personal and private nature. Be honest, direct, polite and respectful.
You may also share the information about your doctor (name), how long you have been living with arthritis, the types of medicines you’ve tried in the past, and how important it is to you that we have more options available to us in the future.
How did you learn about this submission process?
CreakyJoints Australia monitored the submission process and notified the community about this comment period. CreakyJoints Australia is part of the non-profit Global Healthy Living Foundation PTY LTD, based in Australia and headquartered in New York, U.S.A.
Thank you for your time and input!